# Aclaris Therapeutics, Inc. (ACRS): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Aclaris Therapeutics, Inc. (ACRS) is 13/100, ranked against 24,000+ stocks in 35 markets (Quality 21, Value 24, Momentum 45, each scored against its sector).

- StockRank: 13/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 21, Value 24, Momentum 45: each a 0-100 percentile within Healthcare.
- Position: #22,924 overall, #2,150 in Healthcare.
- Listing: United States, NMS; Healthcare / Biotechnology.
- Last close: 3.79 USD on 26 Oct 2026.
- Insider filings, last 180 days: no director or 5%+ holder trades with a stated value.

Source: https://moatmap.ai/stock/ACRS
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker